

**North Central Cancer Treatment Group**

N0877: Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM)

Status Change – October 15, 2009

**NOTICE OF STATUS CHANGE**

This study is re-opened to patient accrual for 3 additional patients on dose level 0. Effective Thursday, October 15, 2009.

**Please retain this notice with the protocol.**